中国中医药信息杂志
中國中醫藥信息雜誌
중국중의약신식잡지
CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE
2014年
6期
27-29
,共3页
幽门螺杆菌相关性胃病%祛菌通幽汤%中西医结合疗法
幽門螺桿菌相關性胃病%祛菌通幽湯%中西醫結閤療法
유문라간균상관성위병%거균통유탕%중서의결합요법
HP associated gastric diseases%Qujun Tongyou Decoction%integrated therapy of traditional Chinese and western medicine
目的:观察祛菌通幽汤替代抗生素治疗幽门螺杆菌(HP)相关性胃病的疗效,并探讨其作用机制。方法236例患者中,初治患者140例,随机分成治疗组80例和对照组60例;复治患者96例,随机分成治疗组56例和对照组40例。对照组予西药四联疗法:初治患者使用雷贝拉唑钠肠溶胶囊+胶体果胶铋+阿莫西林胶囊+克拉霉素分散片;复治患者予雷贝拉唑钠肠溶胶囊+胶体果胶铋+甲硝唑片+左氧氟沙星片。治疗组均使用雷贝拉唑钠肠溶胶囊+胶体果胶铋+祛菌通幽汤。疗程为2周。治疗后1、3、6个月时复查碳14-尿素呼气试验,观察HP转阴、临床症状改善情况及不良反应。结果2组HP转阴率、总有效率及HP复发率比较,差异有统计学意义(P<0.05);2组症状控制率比较,差异有统计学意义(P<0.01);治疗组未见明显不良反应。结论雷贝拉唑钠肠溶胶囊、胶体果胶铋联合祛菌通幽汤能有效抑杀HP,促进HP转阴,减少HP复发,促进胃黏膜炎症修复和溃疡愈合,改善症状,不良反应少,治疗HP相关性胃病有一定疗效。
目的:觀察祛菌通幽湯替代抗生素治療幽門螺桿菌(HP)相關性胃病的療效,併探討其作用機製。方法236例患者中,初治患者140例,隨機分成治療組80例和對照組60例;複治患者96例,隨機分成治療組56例和對照組40例。對照組予西藥四聯療法:初治患者使用雷貝拉唑鈉腸溶膠囊+膠體果膠鉍+阿莫西林膠囊+剋拉黴素分散片;複治患者予雷貝拉唑鈉腸溶膠囊+膠體果膠鉍+甲硝唑片+左氧氟沙星片。治療組均使用雷貝拉唑鈉腸溶膠囊+膠體果膠鉍+祛菌通幽湯。療程為2週。治療後1、3、6箇月時複查碳14-尿素呼氣試驗,觀察HP轉陰、臨床癥狀改善情況及不良反應。結果2組HP轉陰率、總有效率及HP複髮率比較,差異有統計學意義(P<0.05);2組癥狀控製率比較,差異有統計學意義(P<0.01);治療組未見明顯不良反應。結論雷貝拉唑鈉腸溶膠囊、膠體果膠鉍聯閤祛菌通幽湯能有效抑殺HP,促進HP轉陰,減少HP複髮,促進胃黏膜炎癥脩複和潰瘍愈閤,改善癥狀,不良反應少,治療HP相關性胃病有一定療效。
목적:관찰거균통유탕체대항생소치료유문라간균(HP)상관성위병적료효,병탐토기작용궤제。방법236례환자중,초치환자140례,수궤분성치료조80례화대조조60례;복치환자96례,수궤분성치료조56례화대조조40례。대조조여서약사련요법:초치환자사용뢰패랍서납장용효낭+효체과효필+아막서림효낭+극랍매소분산편;복치환자여뢰패랍서납장용효낭+효체과효필+갑초서편+좌양불사성편。치료조균사용뢰패랍서납장용효낭+효체과효필+거균통유탕。료정위2주。치료후1、3、6개월시복사탄14-뇨소호기시험,관찰HP전음、림상증상개선정황급불량반응。결과2조HP전음솔、총유효솔급HP복발솔비교,차이유통계학의의(P<0.05);2조증상공제솔비교,차이유통계학의의(P<0.01);치료조미견명현불량반응。결론뢰패랍서납장용효낭、효체과효필연합거균통유탕능유효억살HP,촉진HP전음,감소HP복발,촉진위점막염증수복화궤양유합,개선증상,불량반응소,치료HP상관성위병유일정료효。
Objective To observe the curative effect of Qujun Tongyou Decoction instead of antibiotics in treatment of Helicobacter pylori (HP) associated gastric disease, and explore the mechanism of action. Methods In 236 patients, 140 cases of newly diagnosed patients were randomly divided into treatment group of 80 cases and control group of 60 cases, 96 cases of retreatment patients were randomly divided into treatment group of 56 cases and control group of 40 cases. The control group was given western quadruple therapy:newly diagnosed patients with rabeprazole sodium enteric-coated capsules+colloidal bismuth pectin+Amoxicillin Capsules+clarithromycin dispersible tablets;retreatment patients with rabeprazole sodium enteric-coated capsules+colloidal bismuth pectin+metronidazole tablets+levofloxacin tablets. The treatment group was given rabeprazole sodium enteric coated capsules and colloidal bismuth pectin plus Qujun Tongyou Decoction. All patients were treated for 2 weeks. 1, 3, 6 months after treatment, 14C-urea breath test was detected, HP negative rate, recurrence rate, clinical symptoms, and adverse reaction were observed. Results HP negative rate, the total effective rate and the recurrence rate in treatment group were different with the control group (P<0.05). There was significant difference in the rate of symptom control between treatment group and the control group (P<0.01). No adverse reaction showed in treatment group. Conclusion Rabeprazole sodium enteric-coated capsules and colloidal bismuth pectin combined with Qujun Tongyou Decotion can effectively inhibit and kill HP, promote the repair and healing of ulcer, control symptoms, reduce HP recurrence, lessen adverse reaction, is effective in the treatment of HP associated gastric diseases.